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Introduction
•
•
•

•
•

Melanoma is the rarest yet most
aggressive of the common forms of skin
cancer
Melanoma brain metastases (MBMs) are
a leading cause of morbidity and mortality
for patients with advanced melanoma
Previous
studies
have
implicated
oxidative phosphorylation (OXPHOS) in
the pathogenesis of MBM and in
suppression of the anti-tumor immune
response
Clinically, MBMs with high OXPHOS had
decreased sensitivity to immunotherapy
and targeted gene therapy
However, the role of OXPHOS in
modulating tumor immunity in MBM
remains unclear

Hypothesis

Drug Treatments: Cells were treated with
complete media, DMSO, and 0.1 - 5 μM of
IPN-60090 (glutaminase inhibitor) and
IACS-010759 (mitochondria complex I
inhibitor).

Results (continued)
Metabolic Effect of OXHPOS
Inhibitors on D4M Cells
(A)

Cellular Metabolism Analysis: The
MitoStress Test was run on Seahorse 96well XF Analyzer to measure oxygen
consumption rate (OCR) of D4M cells 24h
post-drug treatment
Cytokine Analysis: Cell media supernatant
was collected at 24h post-treatment with 1
μM IACS-010759. Cytokine array analysis
was performed using the Mesoscale UPLEX platform to assess the effect of
OXPHOS inhibition on D4M melanoma
secretion of cytokines and chemokines
involved in immune system regulation
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Figure 6: Schematic
showing effect of IACS
on cancer cell survival
and immune evasion
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Results

We hypothesize that OXPHOS suppresses
the immune response in MBMs.

Aim
To better understand the role of OXPHOS in
MBM pathogenesis and immunosuppression,
we
investigated
the
metabolic
and
immunologic effects of pharmacological
OXPHOS inhibitors using IPN-60090 and
IACS-010759 on D4M melanoma cells.
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Figure 2: D4M cell vitality
after blasticidin antibiotic
treatment analyzed by
CTB Assay. Dots
represent mean of
replicates (n=4) and lines
represent SEM.

Methods and Materials

Selection: D4M sensitivity to blasticidin
(Bsd) treatment (0.1 μg/mL – 1000 μg/mL)
was evaluated by Cell Titer Blue (CTB)
assay. Transfected D4M cells underwent
dual-selection with blasticidin antibiotic
treatment (100 μg/mL) and FACS

Conclusions
•

IACS-010759 and IPN-60090 significantly
inhibited OXPHOS levels in D4M cells

•

Treatment with OXPHOS inhibitors
increased the level of certain immune
activators and decreased levels of protumor cytokines secreted by D4M cells
D4M is more sensitive to inhibition of
Complex I than glutaminase inhibition.

D4M Blasticidin Sensitivity
μg/mL Bsd

Fluorescence Tagging: D4M murine
melanoma cells were cultured and stably
transfected with lentiviral particles coexpressing firefly luciferase and RFP, and
blasticidin antibiotic resistance (GenTarget)

OXPHOS Modules the Tumor
Microenvironment

Figure 4: (A) Mitochondrial OXHPOS is represented by the
Oxygen Consumption Rate (OCR) of treated cells (n = 5).
(B) Treatment with 1 uM IACS-010759 and IPN-60090
decreased basal OCR by 86.6% (p<0.0001) and 18.2% (p =
0.056) respectively, and IACS decreased the maximum
OCR level by 66.8% (p<0.0001). Dots represent individual
replicates (n=3) and lines represent SEM.
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Our results are consistent with growing
data showing mitochondrial metabolism
and OXPHOS has diverse and critical
functions in cancer immune evasion.
We plan to further assess the long-term
effects of OXPHOS inhibition on D4M
cytokine expression

Future studies will examine the impact of
the tumor microenvironment in MBM and
how it influences the rate and sensitivity
of OXPHOS in melanoma cells through
co-culture with astrocytes and in animal
models of MBM. Animal studies will utilize
luciferase expression for in-vivo imaging
Better
understanding
of
cancer
metabolism and its effect on immune
response will allow for new, efficient
treatments combining metabolic inhibitors
with immune-checkpoint therapy.

Acknowledgements
(C) Other Cyto-/Chemokines

10x
Luc-RFPBsd vector

D4M PostSelection

80%

References
1. Fischer et al. Clinical, molecular, metabolic, and immune
features associated with oxidative phosphorylation in
melanoma brain metastases. Neurooncol Adv. 2021 Jan
6;3(1):vdaa177.

Antibiotic
treatment

10x

FACS
Figure 1: Schematic showing the
Luc-RFP-Bsd vector used and the
process of tagging and selecting
for RFP+ D4M cells

Research was supported by the Cancer Prevention and Research
Institute of Texas (CPRIT) via Research Training Award RP170067, the
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the
National Center for Advancing Translational Sciences of the National
Institutes of Health (NIH) under Award Numbers TL1TR0003169 and
UL1TR003167, and the MD Anderson ORION Core Facility.

Figure 3: (A) Fluorescent microscopy images of D4M cells
before and after transfection and selection with blasticidin
and FACS. (B) Flow cytometry indicating increasing
percentage of RFP+ D4M cells.

Figure 5: OXHPOS inhibition: (A) Increased expression of
anti-tumorigenic GM-CSF
(p<0.0001) and CXCL10
(p=0.0144), (B) Decreased secretion of pro-tumorigenic CCL2
(p=0.0035), CXCL1 (p<0.0001), and CXCL2 (p=0.034), (C)
Highly increased expression of VEGF (p<0.0001) and CCL4
(p<0.0001).
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